Last quarter's reported loss isn't the problem. Although it was slightly bigger than expected, the analyst community knew the company would likely remain in the red due to a revenue headwind for the ...

View BioNTech SE Sponsored ADR BNTX stock quote prices, financial information, real-time forecasts, and company news from CNN.

BioNTech’s fair value estimate has been trimmed from $139.51 to $131.39, a modest cut of about 6% that reflects the latest model inputs. This shift comes as analysts reassess the story around ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.

BioNTech partners with Boehringer Ingelheim on lung cancer combo therapy, advances malaria vaccine, and plans capital raise to fund 15 Phase 3 oncology trials by 2026.

BioNTech advances its oncology pipeline with strong endometrial cancer data for BNT323, targeting a 2026 FDA filing. A major lung cancer combo trial is also set, backed by a €17B war chest.

BioNTech SE – ADR (NASDAQ: BNTX) reported upbeat fourth-quarter financial results and issued FY26 sales guidance below estimates on Tuesday. BioNTech reported quarterly losses of 38 cents per share ...

Insider Sales Present Buying Opportunity In recent weeks, there have been numerous insider sales at Vidac Pharma. What is ...

While BioNTech's substantial cash reserve of 17.2 billion euros provides a near-term buffer, the company faces a costly transition. Research and development expenses are projected to climb to as much ...

German biopharma outfit BioNTech SE reported lackluster fiscal Q4 results on Tuesday. Guidance for the year now underway is just as disappointing. The creators of this company’s breakthrough science ...